Volume 9, Issue 3 (Vol.9 No.3 Oct 2020)                   rbmb.net 2020, 9(3): 250-256 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohammadi P, Zangeneh M, Mohammadi-Motlagh H, Khademi F. The Antimicrobial Peptide, Nisin, Synergistically Enhances the Cytotoxic and Apoptotic Effects of Rituximab Treatment on Human Burkitt’s Lymphoma Cell Lines. rbmb.net. 2020; 9 (3) :250-256
URL: http://rbmb.net/article-1-468-en.html
Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Abstract:   (338 Views)
Background: Non-Hodgkin’s lymphomas comprise the most common hematological cancers worldwide and consist of a heterogenous group of malignancies affecting the lymphoid system. Treatment of non-Hodgkin’s lymphoma has been significantly enhanced with the addition of Rituximab to the standard chemotherapy regimen. However, even with the advancement of treatment patients continue to relapse and develop resistance to Rituximab, rendering subsequent treatments unsuccessful. The use of novel drugs with unique antitumor mechanisms has gained considerable attention. In this study, we explored the in vitro anti-cancer effects of the combined therapy of Rituximab and Nisin on human Burkitt’s lymphoma cells.

Methods: The human Burkitt’s lymphoma cells lines, Raji and Daudi, were treated with Nisin, Rituximab, or a combination of the two agents at various concentrations. Cytotoxicity following treatment was determined using cell viability assay. The degree of apoptosis was verified via flow cytometric analysis using FITC annexin V/PI staining.

Results: Our findings show that the combined treatment of Rituximab and Nisin results in a more significant reduction in the survival of Raji and Daudi Burkitt’s lymphoma cells, compared to Nisin or Rituximab treatment alone. Additionally, our results indicate that Nisin can induce a significant degree of apoptosis in the Burkitt’s lymphoma cells compared to the negative controls. However, the addition of Nisin to the Rituximab treatment synergistically enhances the apoptotic antitumor effect.

Conclusions: This study demonstrates the synergistic antitumor effect of Nisin treatment in vitro to enhance tumor cell apoptosis and the potential value of Nisin as an adjunct therapy in the treatment of lymphoma.
Full-Text [PDF 876 kb]   (124 Downloads)    
Type of Article: Original Article | Subject: Cell Biology
Received: 2020/02/18 | Accepted: 2020/03/29 | Published: 2020/12/1

References
1. Singh V, Gupta D, Almasan A. Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. J Cancer Sci Ther. 2015;7(11):347-358. [DOI:10.4172/1948-5956.1000373] [PMID] [PMCID]
2. White CA. Rituximab immunotherapy for non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 1999;14(4):241-50. [DOI:10.1089/cbr.1999.14.241] [PMID]
3. Myhr K-M, Torkildsen O, Lossius A, Bo L, Holmoy T. B cell depletion in the treatment of multiple sclerosis. Expert Opin Biol Ther. 2019;19(3):261-271. [DOI:10.1080/14712598.2019.1568407] [PMID]
4. Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8(1):12. [DOI:10.1007/s13317-017-0100-y] [PMID] [PMCID]
5. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-45. https://doi.org/10.1182/blood.V83.2.435.bloodjournal832435 [DOI:10.1182/blood.V83.2.435.435] [PMID]
6. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody Rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900-8. https://doi.org/10.1182/blood.V95.12.3900 [DOI:10.1182/blood.V95.12.3900.012k14_3900_3908] [PMID]
7. Jazirehi AR, Gan X-H, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2003;2(11):1183-93.
8. Goudarzi F, Asadi A, Afsharpour M, Jamadi RH. In Vitro Characterization and Evaluation of the Cytotoxicity Effects of Nisin and Nisin-Loaded PLA-PEG-PLA Nanoparticles on Gastrointestinal (AGS and KYSE-30), Hepatic (HepG2) and Blood (K562) Cancer Cell Lines. AAPS PharmSciTech. 2018;19(4):1554-1566. [DOI:10.1208/s12249-018-0969-4] [PMID]
9. Lewies A, Wentzel JF, Miller HC, Du Plessis LH. The antimicrobial peptide Nisin Z induces selective toxicity and apoptotic cell death in cultured melanoma cells. Biochimie. 2018;144:28-40. [DOI:10.1016/j.biochi.2017.10.009] [PMID]
10. Ahmadi S, Ghollasi M, Hosseini HM. The apoptotic impact of Nisin as a potent bacteriocin on the colon cancer cells. Microb Pathog. 2017;111:193-197. [DOI:10.1016/j.micpath.2017.08.037] [PMID]
11. Kamarajan P, Hayami T, Matte B, Liu Y, Danciu T, Ramamoorthy A, et al. Nisin ZP, a Bacteriocin and Food Preservative, Inhibits Head and Neck Cancer Tumorigenesis and Prolongs Survival. PLoS One. 2015;10(7):e0131008. [DOI:10.1371/journal.pone.0131008] [PMID] [PMCID]
12. Michel-Briand Y, Baysse C. The pyocins of Pseudomonas aeruginosa. Biochimie. 2002;84(5-6):499-510. [DOI:10.1016/S0300-9084(02)01422-0]
13. Paiva AD, de Oliveira MD, de Paula SO, Baracat-Pereira MC, Breukink E, Mantovani HC. Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity. Microbiology. 2012;158(Pt 11):2851-2858. [DOI:10.1099/mic.0.062190-0] [PMID]
14. Cruz-Chamorro L, Puertollano MA, Puertollano E, de Cienfuegos GA, de Pablo MA. In vitro biological activities of magainin alone or in combination with Nisin. Peptides. 2006;27(6):1201-9. [DOI:10.1016/j.peptides.2005.11.008] [PMID]
15. Gaspar D, Veiga AS, Castanho MARB. From antimicrobial to anticancer peptides. Front Microbiol. 2013;4:294. [DOI:10.3389/fmicb.2013.00294] [PMID] [PMCID]
16. Brotz H, Sahl HG. New insights into the mechanism of action of lantibiotics--diverse biological effects by binding to the same molecular target. J Antimicrob Chemother. 2000;46(1):1-6. [DOI:10.1093/jac/46.1.1] [PMID]
17. Joo NE, Ritchie K, Kamarajan P, Miao D, Kapila YL. Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1. Cancer Med. 2012;1(3):295-305. [DOI:10.1002/cam4.35] [PMID] [PMCID]
18. Moll GN, Clark J, Chan WC, Bycroft BW, Roberts GC, Konings WN, et al. Role of transmembrane pH gradient and membrane binding in Nisin pore formation. J Bacteriol. 1997;179(1):135-140. [DOI:10.1128/JB.179.1.135-140.1997] [PMID] [PMCID]
19. Zainodini N, Hassanshahi G, Hajizadeh M, Khanamani Falahati-Pour S, Mahmoodi M, Mirzaei MR. Nisin Induces Cytotoxicity and Apoptosis in Human Asterocytoma Cell Line (SW1088). Asian Pac J Cancer Prev. 2018;19(8):2217-2222.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb